Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 13.9
(17.0%)
HKD 13.9
(17.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -270.28 Million CNY | 55.4% |
| 2022 | -606 Million CNY | -15.33% |
| 2021 | -525.45 Million CNY | -38.18% |
| 2020 | -380.25 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 7.36 Million CNY | 0.0% |
| 2024 Q1 | 7.36 Million CNY | 111.12% |
| 2023 FY | -270.28 Million CNY | 55.4% |
| 2023 Q4 | -66.27 Million CNY | 2.0% |
| 2023 Q3 | -67.62 Million CNY | 13.44% |
| 2023 Q2 | -78.12 Million CNY | 0.0% |
| 2023 Q1 | -78.12 Million CNY | 51.7% |
| 2022 Q1 | -140.54 Million CNY | -0.67% |
| 2022 Q4 | -161.75 Million CNY | 0.0% |
| 2022 FY | -606 Million CNY | -15.33% |
| 2022 Q3 | -161.75 Million CNY | -15.09% |
| 2022 Q2 | -140.54 Million CNY | 0.0% |
| 2021 Q2 | -119.93 Million CNY | 0.0% |
| 2021 FY | -525.45 Million CNY | -38.18% |
| 2021 Q4 | -139.6 Million CNY | 0.0% |
| 2021 Q3 | -139.6 Million CNY | -16.4% |
| 2021 Q1 | -119.93 Million CNY | 0.0% |
| 2020 FY | -380.25 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 498.839% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 130.1% |